Effectiveness of Magnesium Supplementation on Sleep Quality and Mood for Adults with Poor Sleep Quality: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial
Abstract
Objectives: Conduct a randomized double-blind placebo-controlled crossover pilot trial on adults with nonclinical insomnia symptoms to examine the effectiveness of magnesium supplementation on sleep quality and mood. Methods: Participants (N = 31 adults, M age = 46.01) were randomized to either the Magnesium Condition (1 g/d of Upgraded MagnesiumTM) or Placebo Condition for 2 weeks. Following a two-week washout, participants engaged in the alternative condition. Standardized self-reports (i.e., Insomnia Severity Index, Pittsburgh Sleep Quality Index, Restorative Sleep Questionnaire, Pain and Sleep Questionnaire, Flinders Fatigue Scale, Trait Anxiety Inventory, Perceived Stress Scale, and Profile of Mood States) were completed at Baseline and Post Conditions along with daily objective measures of sleep and activity (i.e., Oura Ring) and adverse events. ISRCTN registry number is 70584524. Results: The Magnesium Condition had significant improvements compared to the Placebo Condition for sleep quality, mood, and activity outcomes (e.g., sleep duration, deep sleep, sleep efficiency, readiness, activity balance, and heart rate variability readiness), p’s .05. No adverse events were reported and adherence was 100%. Conclusion: Magnesium supplementation may be an effective nonpharmacological intervention to promote sleep and mood. Longer term clinical trials conducted in a variety of populations and settings are encouraged.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 31 participants or records.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.